PTPRD/PTPRT突变在NSCLC免疫治疗中的意义  

Significance of PTPRD/PTPRT Mutations in Immunotherapy for Non-Small Cell Lung Cancer

作　　者：王昂[1] 崔伟燕[1] 李佳 钟勇伟 邓见明[1] WANG Ang;CUI Weiyan;LI Jia;ZHONG Yongwei;DENG Jianming(Guangdong Second People's Hospital,Guangzhou,Guangdong,China 510317;Gaozhou Traditional Chinese Medicine Hospital,Gaozhou,Guangdong,China 525200)

机构地区：[1]广东省第二人民医院,广东广州510317 [2]广东省高州市中医院,广东高州525200

出　　处：《中国药业》2024年第S02期4-6,共3页China Pharmaceuticals

摘　　要：目的探讨PTPRD/PTPRT突变在非小细胞肺癌(NSCLC)免疫治疗中的意义。方法纳入2个接受免疫治疗的NSCLC公共队列和1个癌症基因组图谱(TCGA)肺癌临床队列,分析NGS测序数据和临床数据;同时纳入1个中国人群NSCLC队列分析PTPRD/PTPRT的突变特征。验证PTPRD/PTPRT突变与非小细胞肺癌免疫治疗疗效的关联。结果与野生型比较,PTPRD/PTPRT突变的NSCLC患者接受免疫治疗有显著更好的无进展生存时间(PFS);PTPRD/PTPRT突变不是NSCLC患者的预后因素。中国NSCLC人群中PTPRD/PTPRT的突变率为2.1%,突变与患者的病理类型、年龄无相关性,但与患者的性别显著相关(P<0.001)。结论PTPRD/PTPRT突变是NSCLC患者接受免疫检查点阻断(ICB)治疗疗效的正相关生物标记物。中国NSCLC人群中PTPRD/PTPRT的突变率为2.1%,男性患者显著高于女性。Objective To investigate the significance of PTPRD/PTPRT mutations in immunotherapy for non-small cell lung cancer(NSCLC).Methods Two NSCLC public cohorts receiving immunotherapy and one Cancer Genome Atlas(TCGA)lung cancer clinical cohort were included,and NGS sequencing data and clinical data were analyzed.At the same time,a Chinese NSCLC cohort was included to analyze the mutation characteristics of PTPRD/PTPRT.The association between PTPRD/PTPRT mutations and the efficacy of immunotherapy for non-small cell lung cancer was verified.Results Compared with the wild-type,NSCLC patients with PTPRD/PTPRT mutations showed significantly better progression free survival(PFS)after receiving immunotherapy;PTPRD/PTPRT mutations were not prognostic factors for NSCLC patients.The mutation rate of PTPRD/PTPRT in the Chinese NSCLC population was 2.1%.The mutation was not correlated with the patient′s pathological type or age,but significantly correlated with the patient′s gender(P<0001).Conclusion PTPRD/PTPRT mutations are positively correlated biomarkers for the efficacy of immune checkpoint blockade(ICB)therapy in NSCLC patients.The mutation rate of PTPRD/PTPRT in the Chinese NSCLC population is 2.1%,the mutation rate in male patients is significantly higher than that in females.

关 键 词：PTPRD/PTPRT 非小细胞肺癌 免疫治疗 中国人群 突变特征 

分 类 号：R979.1[医药卫生—药品]